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435 Development of a secure, on-line clinical health record to
improve care in cystic ﬁbrosis (CF)
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Background: Research into the inﬂuences on the natural history of CF contin-
ues. This has translated into clinical advances in cystic ﬁbrosis care that have
signiﬁcantly increased survival over the past 40 years. Recently, there has been
an increased focus on using information technology. AIM: To develop a secure,
electronic health record for use in CF care (CFeHR).
Method: A consultation process, including pre-implementation surveys, occurred.
An existing chronic illness application was modiﬁed for CF. Hospital systems were
linked to the eHR to capture information required for complex, multi-disciplinary
management.
Results: Survey responders were positive about the proposed CFeHR. Staff spent
in excess of 30 mins/day seeking information in the paper-based record. The
CFeHR is easily navigated. Multiple clinicians can access real-time results and
care plans across settings. Security is via individual certiﬁcates issued by Medicare
Australia. The application uses HL7 messaging to integrate with hospital systems
and interface with the national CF data registry for reporting. Remote consultations
via personal computer video-conferencing with lung function monitoring are also
possible. Change management strategies have also been developed.
Conclusion: Successful implementation of the CFeHRs required stakeholder input,
cooperation with Information Technology personnel and situation-speciﬁc change
management strategies.
Supported by: The Victorian Cystic Fibrosis Clinical Information Management
Program is funded by a Managed Health Network Grant from the Dept of Health
and Aging.
This program has met the requirements of the Bayside Health Ethics Committee.
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Introduction: Acute renal failure is increasingly recognised in cystic ﬁbrosis
patients. It is believed to be related to aminoglycoside use. It is not known how
many cystic ﬁbrosis patients have underlying impaired renal function, or the best
way of assessing this.
Aims: To survey the renal function of a cohort of cystic ﬁbrosis patients using
different formulas for estimating the glomerular ﬁltration rate.
Methods: The estimated glomerular ﬁltration rate (eGFR) was calculated for 109
(56 male) cystic ﬁbrosis patients aged 1 to 15 years old who receive care at Shefﬁeld
Children’s Hospital. Four of the most well used calculations for eGFR (Modiﬁed
Diet in Renal Disease (MDRD), Cockcroft and Gault, Schwartz and Counahan)
were performed.
Results: 38 patients had mildly reduced GFR and 13 patients moderately reduced
GFR with the Cockcroft and Gault calculation. Eight had mild kidney disease
with the Counahan formula. All had normal renal function with MDRD and
Schwartz calculations. On further analysis of the eight patients with mild renal
failure according to the Counahan formula, 3 had further risk factors for having
impaired renal function e.g. PDA ligation, multicystic kidney disease, frequent
courses of tobramycin. These patients will receive further evaluation with a formal
estimate of creatinine clearance.
Conclusion: None of the cystic ﬁbrosis patients in this study were identiﬁed as
having severe renal failure with the calculations used. However the variability of
estimated GFR formulas suggests they are unlikely to be a reliable indicator of renal
function in paediatric cystic ﬁbrosis patients. Those patients who have frequent
courses of aminoglycosides or other risk factors for renal dysfunction will require
close scrutiny. Further prospective evaluation is required.
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Introduction: Many CF women can now expect to bear children, and although
a number of studies have looked at the effect of pregnancy on the CF condition,
there have been none examining its effect on the health care costs of managing
this complex group of patients. To look at this further, using a case control model
we compared the health care burden of pregnancy in 10 patients and 10 controls
attending our adult CF unit.
Methods:We matched patients for age (± 3 years), FEV1 (±15%), weight (±6 kg),
diabetic status and microbiology, with 10 case controls, and compared the number
of clinic visits, hospital admissions, and home IV and oral antibiotic use. In total,
costs were calculated for a 21 month period (the duration of the pregnancy and the
subsequent 12 months).
Results: The pregnant women required more admissions (mean 5.1 [range 0 to 10]
versus 3.8 [0 to 11]), and because of this had fewer courses of home IV therapy
(mean 1.6 [0 to 7] versus 2.5 [0 to 6]. They were also seen more frequently in
clinic (mean 22.5 visits [0 to 36] v 19.8 [14 to 33], and had more courses of oral
antibiotic therapy (mean 2.5 [0 to 6] versus 2 [0 to 4]).
Conclusion: Pregnancy confers an increased burden on the healthcare provision
for CF women. Given the recent emphasis on producing accurate costing structures
for CF care, this consequence of the improving health of the adult CF community
needs to be factored in to ﬁnancial modelling when commissioning services for
this group of patients.
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Introduction: On the one hand chronic rhinosinusitis (CRS) is a hallmark of CF, as
the CFTR-defect equally involves upper airway mucosa. On the other hand allergic
rhinosinusitis is the most frequent chronic disease in the general population. The
aim of our study therefore was to evaluate the role of allergy in CF-associated CRS.
Methods: 145 CF-patients from 5 German centres were assessed for allergic
sensitization by total and speciﬁc serum IgE and for CRS-symptoms with the Sinu-
Nasal-Outcome-Test-20 (SNOT-20) as speciﬁc score for CRS-related quality of life.
Rhinoscopy was performed, and anti-allergic medication was quoted.
Results: 63/145 CF-patients report allergy symptoms but only 42 (67%) resulted
positive in allergy testing. 46/145 patients (32%) suffered from CRS according to
EPOS 2007 criteria and 49 (34%) had acute intermittent symptoms (<12 weeks a
year). 50 (34%) did not fulﬁl the EPOS criteria but 15 of them reported on remittent
or chronic nasal discharge.
Of the 46 patients with CRS, 20 (43%) showed allergic sensitization with speciﬁc
IgE of at least CAP-class 2 (>0.70 kU/l).
Discussion: About 1/3 of CF-patients suffers from chronic and 1/3 from remittent
rhinosinusitis. The proportion which estimates to be allergic is considerably higher
than the proportion of patients with proven sensitization. This shows that the role
of CF-related chronic rhinosinusitis in CF itself is relevantly underestimated.
